Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
Metsera shares leap on strong IPO performance
Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, despite more negative than positive news.
Metsera sees stock rally 54% following $275M IPO
Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25.50 after being priced at $18 per share,
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and related conditions. Read our initial report here on Seeking Alpha.
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.
FierceBiotech13h
Sionna eyes up $156M IPO to fund cystic fibrosis trials
Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...
Metsera Announces Pricing of Initial Public Offering
A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
FierceBiotech7d
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
devdiscourse1d
Health Headlines: A Global Perspective on Innovations and Challenges
Recent health news covers significant events like Pfizer's diversity program settlement, AstraZeneca's halted UK investment, ...